Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway

Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Protara Therapeutics, retaining the price target of $26.00.

Charles Zhu has given his Buy rating due to a combination of factors tied to both clinical momentum and strategic positioning of TARA-002. Management highlighted that the therapy delivered what they view as a best‑in‑class six‑month complete response rate in BCG‑unresponsive NMIBC, and they remain optimistic that longer‑term durability data will improve as additional patients mature, potentially restoring response rates into a more competitive range.

Zhu also underscores that TARA has secured FDA alignment on a sizable randomized Phase 3 trial in BCG‑naïve patients, targeting a meaningful population unable or unwilling to receive standard BCG therapy. In addition, TARA-002 offers a differentiated, broad‑based immunopotentiator mechanism that stands apart from existing targeted therapies, and with over two years of cash runway, the company appears positioned to advance these pivotal programs, supporting a favorable risk‑reward profile for the stock.

In another report released on March 12, J.P. Morgan also maintained a Buy rating on the stock with a $27.00 price target.